سعر ليريمار 20 مجم 10 كبسولات 2022

Lirimar atorvastatin 20 mg hard capsules, pack of 10 (Riva Pharma, Egypt); HMG-CoA reductase inhibitor (statin) for lowering cholesterol.

• US-labelled uses of atorvastatin: reduce the risk of MI, stroke, revascularisation and angina in adults with CHD risk factors or clinically evident CHD; adjunct to diet to lower LDL-C in primary hyperlipidaemia and HeFH (age 10+), HoFH, primary dysbetalipoproteinaemia and hypertriglyceridaemia.Population: Adults; paediatric patients 10 years and older for HeFH/HoFHDailyMed (U.S. National Library of Medicine)

• Most common in placebo-controlled trials (any dose, >=2% and above placebo): nasopharyngitis 8.3%, arthralgia 6.9%, diarrhoea 6.8%, pain in extremity 6.0%, urinary tract infection 5.7%, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia and pharyngolaryngeal pain.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Acute liver failure or decompensated cirrhosis; hypersensitivity to atorvastatin or any excipient (anaphylaxis, angioneurotic oedema, erythema multiforme, SJS and TEN reported).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis: risk rises with age 65 years or more, uncontrolled hypothyroidism, renal impairment, interacting drugs (CYP3A4/transporter inhibitors) and higher doses; stop if CK is markedly raised or myopathy is suspected; patients should report unexplained muscle pain, tenderness or weakness.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotising myopathy (rare): proximal weakness with persistently raised CK despite stopping the statin; discontinue if suspected.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: transaminase rises (persistent >3x ULN in about 0.7%); consider liver tests before starting and when clinically indicated; stop promptly if serious liver injury with symptoms, hyperbilirubinaemia or jaundice occurs; higher risk with heavy alcohol use or liver disease.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Cyclosporine, gemfibrozil, tipranavir plus ritonavir, glecaprevir plus pibrentasvirConcomitant use not recommended because atorvastatin exposure and myopathy/rhabdomyolysis risk increase.DailyMed (U.S. National Library of Medicine)
• Clarithromycin, itraconazole, saquinavir/ritonavir, darunavir/ritonavir, fosamprenavir, elbasvir/grazoprevir, letermovirDo not exceed atorvastatin 20 mg once daily with these drugs (US label dose cap).DailyMed (U.S. National Library of Medicine)
• Grapefruit juice (more than 1.2 litres daily)Large quantities raise atorvastatin levels and myopathy risk; avoid more than 1.2 L daily.DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognised (or weigh ongoing need); may cause fetal harm by mechanism, although observational data over decades have not identified an increased risk of major malformations; treatment of hyperlipidaemia is generally not needed in pregnancy.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• No human data; atorvastatin is present in rat milk and statins may harm the breastfed infant: breastfeeding is not recommended during treatment.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Atorvastatin: Inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis.